CN103585126A - Tofacitinib composition and preparation method thereof - Google Patents
Tofacitinib composition and preparation method thereof Download PDFInfo
- Publication number
- CN103585126A CN103585126A CN201310581713.7A CN201310581713A CN103585126A CN 103585126 A CN103585126 A CN 103585126A CN 201310581713 A CN201310581713 A CN 201310581713A CN 103585126 A CN103585126 A CN 103585126A
- Authority
- CN
- China
- Prior art keywords
- buddhist nun
- strengthening vital
- expelling pathogens
- pharmaceutical composition
- pathogens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a tofacitinib composition and a preparation method thereof, and belongs to the technical field of medicines. Tofacitinib is an active component, is matched with pharmaceutically acceptable auxiliary materials, and is prepared into the tofacitinib composition by adopting the existing preparation technique. The preparation technique accords with the production requirements, and can guarantee the stability and safety of the preparation. The tofacitinib composition is convenient to transport and preserve, and provides a novel medicine selection for the active phase of adults and the moderate or severe patients suffered from rheumatoid arthritis and not responding well to methotrexate.
Description
Technical field: this relates to a kind of expelling pathogens by strengthening vital QI for Buddhist nun's pharmaceutical composition and preparation method, belongs to medical technical field.
Background technology:
Expelling pathogens by strengthening vital QI for Buddhist nun be a kind of Janus inhibitors of kinases, for methotrexate for treatment is replied insufficient or do not tolerate to severe active rheumatoid arthritis (RA) adult patient.Different in extracellular target spot from other RA medicine Main Functions of current majority, expelling pathogens by strengthening vital QI be take intracellular signal transduction path as target spot for Buddhist nun, acts on the core of cytokine network.Expelling pathogens by strengthening vital QI is to 5～100 of JAK1 and JAK2 times for Buddhist nun (tofacitinib) to the inhibition strength of JAK3.Expelling pathogens by strengthening vital QI is that exploitation is for the pioneering medicine (first-in-class drug) of rheumatoid arthritis treatment for Buddhist nun.
Summary of the invention:
The object of the present invention is to provide a kind of expelling pathogens by strengthening vital QI for Buddhist nun's pharmaceutical composition and preparation method thereof, for provide clinically a kind of economy, safely, facilitate antirheumatic.
The present invention aims to provide a kind of expelling pathogens by strengthening vital QI for Buddhist nun's pharmaceutical composition, it is characterized in that containing active component expelling pathogens by strengthening vital QI for Buddhist nun or its esters and pharmaceutically acceptable excipient substance.
Described expelling pathogens by strengthening vital QI, for Buddhist nun's pharmaceutical composition, is characterized in that described excipient substance is one or more in microcrystalline Cellulose, Lactis Anhydrous, lactose monohydrate, starch, hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, polyvinylpyrrolidone, crospolyvinylpyrrolidone, magnesium stearate, silicon dioxide.
Described expelling pathogens by strengthening vital QI, for Buddhist nun's pharmaceutical composition, is characterized in that active component is that expelling pathogens by strengthening vital QI replaces Buddhist nun or citric acid expelling pathogens by strengthening vital QI for Buddhist nun.
Described expelling pathogens by strengthening vital QI replaces Buddhist nun's pharmaceutical composition, it is characterized in that, active component and excipient substance quality ratio range are: 1:10-1:90, preferably 1:12-1:50, more preferably 1:15-1:30, most preferably 1:20-1:25.
Described expelling pathogens by strengthening vital QI replaces Buddhist nun's pharmaceutical composition, it is characterized in that, final products are made tablet, capsule or granule, preferred tablet.
Described expelling pathogens by strengthening vital QI, for the preparation method of Buddhist nun's pharmaceutical composition, is characterized in that wet granulation dry granulation alive, preferably wet granulation.
Described expelling pathogens by strengthening vital QI for the preparation method of Buddhist nun's pharmaceutical composition, is characterized in that, comprises following steps;
A): expelling pathogens by strengthening vital QI is replaced to Buddhist nun and excipient substance mix homogeneously;
B): adopt appropriate water to make soft material; And make 18-30 order granule;
C): after dry, obtain dry granule, add hard magnesium, silicon dioxide, by every, containing expelling pathogens by strengthening vital QI, replace Buddhist nun 5mg tabletting, both.
Described expelling pathogens by strengthening vital QI, for Buddhist nun's pharmaceutical composition, is characterized in that preparing the purposes of rheumatism or rheumatoid arthritis.
The specific embodiment:
Below in conjunction with specific embodiment, the invention will be further described, to help understanding content of the present invention.
Example one
Method for making: A): expelling pathogens by strengthening vital QI is replaced to Buddhist nun and excipient substance mix homogeneously;
B): adopt appropriate water to make soft material; And make 18-30 order granule;
C): after dry, obtain dry granule, add hard magnesium, silicon dioxide, by every, containing expelling pathogens by strengthening vital QI, replace Buddhist nun 5mg tabletting, both.
Example two
Method for making: A): expelling pathogens by strengthening vital QI is replaced to Buddhist nun and excipient substance mix homogeneously;
B): adopt appropriate water to make soft material; And make 18-30 order granule;
C): after dry, obtain dry granule, add hard magnesium, silicon dioxide, by every, containing expelling pathogens by strengthening vital QI, replace Buddhist nun 5mg tabletting, both.
Claims (8)
1. expelling pathogens by strengthening vital QI, for Buddhist nun's pharmaceutical composition, contains active component expelling pathogens by strengthening vital QI for Buddhist nun or its esters and pharmaceutically acceptable excipient substance.
2. described in claims 1, expelling pathogens by strengthening vital QI, for Buddhist nun's pharmaceutical composition, is characterized in that described excipient substance is one or more in microcrystalline Cellulose, Lactis Anhydrous, lactose monohydrate, starch, hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, polyvinylpyrrolidone, crospolyvinylpyrrolidone, magnesium stearate, silicon dioxide.
3. expelling pathogens by strengthening vital QI, for Buddhist nun's pharmaceutical composition, is characterized in that active component is that expelling pathogens by strengthening vital QI replaces Buddhist nun or citric acid expelling pathogens by strengthening vital QI for Buddhist nun as claimed in claim 1.
4. expelling pathogens by strengthening vital QI, for Buddhist nun's pharmaceutical composition, is characterized in that as claimed in claim 3, and active component and excipient substance quality ratio range are: 1:10-1:90, preferably 1:12-1:50, more preferably 1:15-1:30, most preferably 1:20-1:25.
5. expelling pathogens by strengthening vital QI, for Buddhist nun's pharmaceutical composition, is characterized in that as claimed in claim 4, and final products are made tablet, capsule or granule, preferred tablet.
6. as described in as arbitrary in claim 1-5, expelling pathogens by strengthening vital QI is for the preparation method of Buddhist nun's pharmaceutical composition, it is characterized in that wet granulation live dry granulation, preferably wet granulation.
7. described in claim 6, expelling pathogens by strengthening vital QI, for the preparation method of Buddhist nun's pharmaceutical composition, is characterized in that, comprises following steps;
A): expelling pathogens by strengthening vital QI is replaced to Buddhist nun and excipient substance mix homogeneously;
B): adopt appropriate water to make soft material; And make 18-30 order granule;
C): after dry, obtain dry granule, add hard magnesium, silicon dioxide, by every, containing expelling pathogens by strengthening vital QI, replace Buddhist nun 5mg tabletting, both.
8. described in claim 1-7, expelling pathogens by strengthening vital QI, for Buddhist nun's pharmaceutical composition, is characterized in that preparing the purposes of rheumatism or rheumatoid arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310581713.7A CN103585126A (en) | 2013-11-18 | 2013-11-18 | Tofacitinib composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310581713.7A CN103585126A (en) | 2013-11-18 | 2013-11-18 | Tofacitinib composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103585126A true CN103585126A (en) | 2014-02-19 |
Family
ID=50075582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310581713.7A Pending CN103585126A (en) | 2013-11-18 | 2013-11-18 | Tofacitinib composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103585126A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845302A (en) * | 2014-03-24 | 2014-06-11 | 江苏圣宝罗药业有限公司 | Tofacitinib tablet with excellent property |
| CN104622827A (en) * | 2015-03-05 | 2015-05-20 | 重庆华邦制药有限公司 | Tofacitinib tablet and preparation method thereof |
| CN105878202A (en) * | 2016-05-27 | 2016-08-24 | 湖北丽益医药科技有限公司 | Tofacitinib citrate tablet and preparation method thereof |
| CN106176640A (en) * | 2014-11-28 | 2016-12-07 | 四川海思科制药有限公司 | Pharmaceutical composition containing tofacitinib citrate and preparation method thereof |
| CN106370757A (en) * | 2016-11-16 | 2017-02-01 | 杭州朱养心药业有限公司 | Tofacitinib citrate tablet pharmaceutical composition and quality control method |
| CN106389371A (en) * | 2016-11-16 | 2017-02-15 | 杭州朱养心药业有限公司 | Tofacitinib citrate pharmaceutical composition |
| CN106420648A (en) * | 2016-11-22 | 2017-02-22 | 山东淄博新达制药有限公司 | Tofacitinib citrate tablet and preparation method thereof |
| CN108640921A (en) * | 2018-04-03 | 2018-10-12 | 山东科兴生物制品有限公司 | Preparation method of tofacitinib citrate |
| CN110946834A (en) * | 2018-09-27 | 2020-04-03 | 四川科伦药物研究院有限公司 | Tofacitinib citrate tablet and preparation process thereof |
| WO2020135401A1 (en) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound |
| WO2021129735A1 (en) * | 2019-12-25 | 2021-07-01 | 上海宣泰医药科技股份有限公司 | Solid preparation, and preparation method therefor and use thereof |
| RU2810112C2 (en) * | 2018-12-24 | 2023-12-21 | Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. | Medical use of pyrrolopyrimidine compound and solid pharmaceutical composition of pyrrolopyrimidine compound |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325498A (en) * | 1998-11-07 | 2001-12-05 | 泰科电子雷伊化学有限公司 | A panel for supporting a plurality of fibre optic connectors |
| CN1325498C (en) * | 2001-12-06 | 2007-07-11 | 辉瑞产品公司 | Novel crystalline compound |
| WO2012100949A1 (en) * | 2011-01-27 | 2012-08-02 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising tasocitinib |
-
2013
- 2013-11-18 CN CN201310581713.7A patent/CN103585126A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325498A (en) * | 1998-11-07 | 2001-12-05 | 泰科电子雷伊化学有限公司 | A panel for supporting a plurality of fibre optic connectors |
| CN1325498C (en) * | 2001-12-06 | 2007-07-11 | 辉瑞产品公司 | Novel crystalline compound |
| WO2012100949A1 (en) * | 2011-01-27 | 2012-08-02 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising tasocitinib |
Non-Patent Citations (2)
| Title |
|---|
| 元英进 主编: "《现代制药工艺学下册》", 31 January 2006 * |
| 杨智 等: "ＪＡＫ３抑制剂托法替尼治疗类风湿关节炎研究进展", 《国际骨科学杂志》 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845302B (en) * | 2014-03-24 | 2016-03-30 | 江苏知原药业有限公司 | A kind of expelling pathogens by strengthening vital QI of excellent performance replaces the tablet of Buddhist nun |
| CN103845302A (en) * | 2014-03-24 | 2014-06-11 | 江苏圣宝罗药业有限公司 | Tofacitinib tablet with excellent property |
| CN106176640A (en) * | 2014-11-28 | 2016-12-07 | 四川海思科制药有限公司 | Pharmaceutical composition containing tofacitinib citrate and preparation method thereof |
| CN104622827A (en) * | 2015-03-05 | 2015-05-20 | 重庆华邦制药有限公司 | Tofacitinib tablet and preparation method thereof |
| CN105878202A (en) * | 2016-05-27 | 2016-08-24 | 湖北丽益医药科技有限公司 | Tofacitinib citrate tablet and preparation method thereof |
| CN106389371B (en) * | 2016-11-16 | 2019-03-15 | 杭州朱养心药业有限公司 | tofacitinib citrate pharmaceutical composition |
| CN106370757A (en) * | 2016-11-16 | 2017-02-01 | 杭州朱养心药业有限公司 | Tofacitinib citrate tablet pharmaceutical composition and quality control method |
| CN106389371A (en) * | 2016-11-16 | 2017-02-15 | 杭州朱养心药业有限公司 | Tofacitinib citrate pharmaceutical composition |
| CN106420648A (en) * | 2016-11-22 | 2017-02-22 | 山东淄博新达制药有限公司 | Tofacitinib citrate tablet and preparation method thereof |
| CN108640921A (en) * | 2018-04-03 | 2018-10-12 | 山东科兴生物制品有限公司 | Preparation method of tofacitinib citrate |
| CN110946834A (en) * | 2018-09-27 | 2020-04-03 | 四川科伦药物研究院有限公司 | Tofacitinib citrate tablet and preparation process thereof |
| WO2020135401A1 (en) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound |
| CN113242859A (en) * | 2018-12-24 | 2021-08-10 | 正大天晴药业集团股份有限公司 | Therapeutic use of pyrrolopyrimidine compounds and solid pharmaceutical compositions thereof |
| RU2810112C2 (en) * | 2018-12-24 | 2023-12-21 | Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. | Medical use of pyrrolopyrimidine compound and solid pharmaceutical composition of pyrrolopyrimidine compound |
| WO2021129735A1 (en) * | 2019-12-25 | 2021-07-01 | 上海宣泰医药科技股份有限公司 | Solid preparation, and preparation method therefor and use thereof |
| EP4082534A4 (en) * | 2019-12-25 | 2023-12-13 | Sinotherapeutics Inc. | Solid preparation, and preparation method therefor and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585126A (en) | Tofacitinib composition and preparation method thereof | |
| RU2616516C2 (en) | Pharmaceutical composition containing olmesartan medoxomil and rosuvastatin or its salt | |
| TWI700100B (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof | |
| PH12015500313A1 (en) | Orally administered medical composition | |
| JP6073543B2 (en) | Method for producing loratadine-containing orally disintegrating tablet | |
| KR102631488B1 (en) | Orally disintegrating tablets containing diamine derivatives | |
| CN105982072A (en) | Vitamin D3 calcium carbonate oral cavity instant films and preparation method thereof | |
| WO2012173581A4 (en) | Thiocolchicoside, etodolac and famotidine combinations | |
| CN103070865A (en) | Oral solid preparation taking prucalopride succinate as active ingredient and application of oral solid preparation | |
| KR102191468B1 (en) | Ultrafast-disintegrating tablet and method for manufacturing same | |
| JP2011246428A (en) | Orally disintegrating medicine and production method | |
| CN109157527B (en) | Irbesartan capsule and preparation method thereof | |
| JP5823592B2 (en) | Formulation with improved stability | |
| JP6373616B2 (en) | Oral composition | |
| JP6469234B2 (en) | Super-fast disintegrating tablet and method for producing the same | |
| WO2016103904A1 (en) | Very rapidly disintegrating tablet, and method for producing same | |
| CN103860511B (en) | A kind of Pharmaceutical composition containing Irbesartan and Amlodipine Besylate Tablet and preparation method thereof | |
| KR101524264B1 (en) | Oral pharmaceutical composition containing valsartan | |
| CN102552170A (en) | Solid preparation taking prasugrel benzene sulfonate as active component | |
| JP6351934B2 (en) | Method for producing orally disintegrating tablets for food | |
| JP6012373B2 (en) | Orally disintegrating tablets | |
| CN103385857A (en) | Pharmaceutical composition of palipeddone | |
| CN104000821B (en) | Oral double-layer tablet containing telmisartan and amlodipine besylate and preparation method thereof | |
| CN103565788A (en) | Pharmaceutical composition for treating depression and preparation method thereof | |
| JP2018048136A (en) | Tablet and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140219 |